The drugs are indicated for adults with locally advanced or metastatic non-small cell lung cancer with select mutations. They are the nation’s “first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus osimertinib” approved for this patient population, J&J said.
Osimertinib is approved to treat non-small cell lung cancer with these mutations.
The five-year survival rate is less than 20% for patients treated with monotherapy, according to J&J. A phase 3 trial showed that Rybrevant and Lazcluze reduced the risk of disease progression or death by 30% compared to osimertinib.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.